Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fuji
Dow
Cerilliant
Chubb
Deloitte
US Army
Harvard Business School
Queensland Health

Generated: November 14, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021802

« Back to Dashboard

NDA 021802 describes FOCALIN XR, which is a drug marketed by Novartis and is included in one NDA. It is available from three suppliers. There are two patents protecting this drug and six Paragraph IV challenges. Additional details are available on the FOCALIN XR profile page.

The generic ingredient in FOCALIN XR is dexmethylphenidate hydrochloride. There are six drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the dexmethylphenidate hydrochloride profile page.
Summary for 021802
Tradename:FOCALIN XR
Applicant:Novartis
Ingredient:dexmethylphenidate hydrochloride
Patents:2
Pharmacology for NDA: 021802
Medical Subject Heading (MeSH) Categories for 021802
Suppliers and Packaging for NDA: 021802
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FOCALIN XR dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021802 NDA Novartis Pharmaceuticals Corporation 0078-0430 0078-0430-05 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0078-0430-05)
FOCALIN XR dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021802 NDA Novartis Pharmaceuticals Corporation 0078-0431 0078-0431-05 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0078-0431-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength5MG
Approval Date:May 26, 2005TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Nov 1, 2019Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
Patent:➤ Sign UpPatent Expiration:Nov 1, 2019Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength10MG
Approval Date:May 26, 2005TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Nov 1, 2019Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION

Expired US Patents for NDA 021802

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis FOCALIN XR dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021802-006 Aug 11, 2010 ➤ Sign Up ➤ Sign Up
Novartis FOCALIN XR dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021802-004 Aug 1, 2006 ➤ Sign Up ➤ Sign Up
Novartis FOCALIN XR dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021802-003 May 26, 2005 ➤ Sign Up ➤ Sign Up
Novartis FOCALIN XR dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021802-005 Oct 23, 2009 ➤ Sign Up ➤ Sign Up
Novartis FOCALIN XR dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021802-007 Apr 21, 2011 ➤ Sign Up ➤ Sign Up
Novartis FOCALIN XR dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021802-008 Apr 21, 2011 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Baxter
McKesson
Merck
Healthtrust
Dow
Deloitte
Harvard Business School
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.